A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.

A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vehicle in the Treatment of Bacterial Conjunctivitis.

NCT00347932•Bausch & Lomb Incorporated

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Acute Bacterial Conjunctivitis

Interventions

ISV-403

Vehicle

Key Dates

Start Date

June 1, 2006

Primary Completion Date

November 1, 2007

Completion Date

November 1, 2007

Last Updated

March 24, 2015

Sponsors

Lead Sponsor

Bausch & Lomb Incorporated

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 24, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions